about
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomizPalonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Emerging drugs for chemotherapy-induced emesis.Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.Prevention and management of chemotherapy-induced nausea and vomiting.Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients.Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.
P2860
Q34166946-B7F10142-D7D0-4EEE-851A-C1E615F18BF6Q34327488-4D4824A7-7EC3-41BA-9669-218CAD145296Q34418467-F94E3476-6F7F-42AB-BB60-2115D69F6DD2Q35028927-4FA30511-82A4-48C1-BAE2-6B3F96EE6646Q35082647-F38ADD82-1DEC-468B-9BF3-1DDFBE8E87A1Q35146420-A9C607FA-2C4E-48E7-9203-ECA5B3E98208Q36064834-6E9D81E6-A401-482F-B755-38A5A5EB25D0Q36407422-E670B9F8-0BDC-483F-92A3-8F82BE9F11B0Q36613996-C208F5A5-69DF-4831-A93C-71DB7295E59AQ36616499-87F275BB-7EAB-46C1-AE73-F4E54CFD1F2EQ37387345-81ECEE4B-5F63-4DF0-B4DA-9B1B9D968392Q37636028-519B6E5E-02B6-42DE-B885-7776C3732929Q37673503-8526B0FC-ADB7-4B5F-8556-CBD44899F664Q37771953-961CB8B9-C40A-4DD4-A7CD-1AAAA30D8E6EQ37816245-58D11D16-720E-4216-B5E1-80F96B95B906Q38260952-4AB1D13F-B627-4314-8921-71199E84FC22Q38264147-D388710A-F059-4804-8796-3B6DB2D2842EQ40801409-62FA6845-BB83-459B-A16C-F08EB571D0D8Q48687384-7B252D0E-26AB-454F-8F73-0AE9A3FC2BDFQ50884329-11506810-E0DF-4B7F-A12D-A34457A4A4B2Q55666180-6E4F561D-41E2-4F32-9ADA-53E29826BBC6
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Delayed emesis: moderately emetogenic chemotherapy.
@ast
Delayed emesis: moderately emetogenic chemotherapy.
@en
type
label
Delayed emesis: moderately emetogenic chemotherapy.
@ast
Delayed emesis: moderately emetogenic chemotherapy.
@en
prefLabel
Delayed emesis: moderately emetogenic chemotherapy.
@ast
Delayed emesis: moderately emetogenic chemotherapy.
@en
P2093
P1476
Delayed emesis: moderately emetogenic chemotherapy.
@en
P2093
David Warr
Fausto Roila
Jorn Herrstedt
Lawrence H Einhorn
Maurizio Tonato
Rebecca A Clark-Snow
Richard J Gralla
P2888
P304
P356
10.1007/S00520-004-0700-8
P577
2004-11-12T00:00:00Z